Although a high degree of selectivity was achieved in these cell lines, the majority of BRAF V600E-bearing cancers are heterozygous, and SJF-0628 has not been extensively tested in these cancer types due to ineffective responses to BRAF-targeted treatment [37,38,39]. This evidence concerns the gene BRAF and cancer.